Alzheon's tramiprosate shows meaningful effects in Alzheimer's trial

12 March 2016

Closely-held US biotech firm Alzheon has presented positive new data analyses from two Phase III studies of tramiprosate in Alzheimer’s disease (AD) patients based on their APOE4 genotype, at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies Conference, held March 9-12 in Athens, Greece

Tramiprosate is the biologically active agent of ALZ-801, a prodrug developed by Alzheon and currently being advanced into pivotal Phase III studies in AD patients with the APOE4/4 homozygous genotype, a patient population known to have high prevalence and burden of cortical amyloid pathology, a hallmark of Alzheimer’s disease.

Drug previously abandoned by Neurochem

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK